ABBOTT LABORATORIES — Director's Dealing 2020

Feb 25, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2020-02-21

Reporting Person: Moreland Mary K (Executive Vice President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-21	Common shares without par value	A	14326	—	Acquired	67311	Direct
2020-02-22	Common shares without par value	F	780	$87.45	Disposed	66531	Direct
2020-02-25	Common shares without par value	S	400	$84.93	Disposed	66131	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-21	Option (right to buy)	$87.72	A	87334	Acquired	2030-02-20	Common shares (87334)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	10673	Indirect

Footnotes

F1: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

F2: Balance in the Abbott Laboratories Stock Retirement Trust as of February 21, 2020.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 29,111 on February 21, 2021, 29,111 on February 21, 2022, and 29,112 on February 21, 2023.